Molecular determinants of inverse agonist activity of biologicals targeting CTLA-4

Journal of Immunology

Volumn 179, Issue 6, 2007, Pages 3631-3637

  Teft, Wendy A ^a,b   Madrenas, Joaquín ^a,b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; BISPECIFIC ANTIBODY; CD28 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2; OLIGOMER; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE RECEPTOR; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; DIFFERENTIATION ANTIGEN; DOXYCYCLINE; GROWTH INHIBITOR; LEUKOCYTE ANTIGEN; LIGAND; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CELL SURFACE; CONTROLLED STUDY; CYTOPLASM; HUMAN; HUMAN CELL; INVERSE AGONISM; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; BIOSYNTHESIS; COMPARATIVE STUDY; DIMERIZATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; GENE DELETION; GENETICS; IMMUNOLOGY; LEUKEMIA CELL LINE; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANTIBODIES, BISPECIFIC; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, DIFFERENTIATION; CYTOPLASM; DIMERIZATION; DOXYCYCLINE; DRUG DELIVERY SYSTEMS; GROWTH INHIBITORS; HUMANS; JURKAT CELLS; LIGANDS; LYMPHOCYTE ACTIVATION; SEQUENCE DELETION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 35748936776     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.6.3631     Document Type: Article

References (39)

1. Teft, W. A., M. G. Kirchhof, and J. Madrenas. 2006. A molecular perspective of CTLA-4 function. Annu. Rev. Immunol. 24: 65-97.
2. Siefken, R., R. Kurrle, and R. Schwinzer. 1997. CD28-mediated activation of resting human T cells without costimulation of the CD3/TCR complex. Cell. Immunol. 176: 59-65.
3. Luhder, F., Y. Huang, K. M. Dennehy, C. Guntermann, I. Muller, E. Winkler, T. Kerkau, S. Ikemizu, S. J. Davis, T. Hanke, and T. Hunig. 2003. Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J. Exp. Med. 197: 955-966.
4. Tacke, M., G. Hanke, T. Hanke, and T. Hunig. 1997. CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28. Eur. J. Immunol. 27: 239-247.
5. Linsley, P. S., J. L. Greene, P. Tan, J. Bradshaw, J. A. Ledbetter, C. Anasetti, and N. K. Damle. 1992. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J. Exp. Med. 176: 1595-1604.
6. Wu, Y., Y. Guo, A. Huang, P. Zheng, and Y. Liu. 1997. CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion. J. Exp. Med. 185: 1327-1335.
7. Kwon, H., H. S. Jun, L. Y. Khil, and J. W. Yoon. 2004. Role of CTLA-4 in the activation of single- and double-positive thymocytes. J. Immunol. 173: 6645-6653.
8. Pandiyan, P., D. Gartner, O. Soezeri, A. Radbruch, K. Schulze-Osthoff, and M. C. Brunner-Weinzierl. 2004. CD152 (CTLA-4) determines the unequal resistance of Th1 and Th2 cells against activation-induced cell death by a mechanism requiring PI3 kinase function. J. Exp. Med. 199: 831-842.
9. Madrenas, J., L. A. Chau, W. A. Teft, P. W. Wu, J. Jussif, M. Kasaian, B. M. Carreno, and V. Ling. 2004. Conversion of CTLA-4 from inhibitor to activator of T cells with a bispecific tandem single-chain Fv ligand. J. Immunol. 172: 5948-5956.
10. Melero, I., S. Hervas-Stubbs, M. Glennie, D. M. Pardoll, and L. Chen. 2007. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer 7: 95-106.
11. Bluestone, J. A., E. W. St Clair, and L. A. Turka. 2006. CTLA4Ig: bridging the basic immunology with clinical application. Immunity 24: 233-238.
12. Suntharalingam, G., M. R. Perry, S. Ward, S. J. Brett, A. Castello-Cortes, M. D. Brunner, and N. Panoskaltsis. 2006. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355: 1018-1028.
13. Baroja, M. L., D. Luxenberg, T. Chau, V. Ling, C. A. Strathdee, B. M. Carreno, and J. Madrenas. 2000. The inhibitory function of CTLA-4 does not require its tyrosine phosphorylation. J. Immunol. 164: 49-55.
14. Baroja, M. L., L. Vijayakrishnan, E. Bettelli, P. J. Darlington, T. A. Chau, V. Ling, M. Collins, B. M. Carreno, J. Madrenas, and V. K. Kuchroo. 2002. Inhibition of CTLA-4 function by the regulatory subunit of serine/threonine phosphatase 2A. J. Immunol. 168: 5070-5078.
15. Carreno, B. M., F. Bennett, T. A. Chau, V. Ling, D. Luxenberg, J. Jussif, M. L. Baroja, and J. Madrenas. 2000. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. J. Immunol. 165: 1352-1356.
16. Darlington, P. J., M. L. Baroja, T. A. Chau, E. Siu, V. Ling, B. M. Carreno, and J. Madrenas. 2002. Surface cytotoxic T lymphocyte-associated antigen 4 partitions within lipid rafts and relocates to the immunological synapse under conditions of inhibition of T cell activation. J. Exp. Med. 195: 1337-1347.
17. Darlington, P. J., M. G. Kirchhof, G. Criado, J. Sondhi, and J. Madrenas. 2005. Hierarchical regulation of CTLA-4 dimer-based lattice formation and its biological relevance for T cell inactivation. J. Immunol. 175: 996-1004.
18. Linsley, P. S., W. Brady, M. Urnes, L. S. Grosmaire, N. K. Damle, and J. A. Ledbetter. 1991. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174: 561-569.
19. Freeman, G. J., F. Borriello, R. J. Hodes, H. Reiser, J. G. Gribben, J. W. Ng, J. Kim, J. M. Goldberg, K. Hathcock, G. Laszlo, et al. 1993. Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J. Exp. Med. 178: 2185-2192.
20. Freeman, G. J., J. G. Gribben, V. A. Boussiotis, J. W. Ng, V. A. Restivo, Jr., L. A. Lombard, G. S. Gray, and L. M. Nadler. 1993. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262: 909-911.
21. Hathcock, K. S., G. Laszlo, C. Pucillo, P. Linsley, and R. J. Hodes. 1994. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. 180: 631-640.
22. Lenschow, D. J., T. L. Walunas, and J. A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14: 233-258.
23. Stamper, C. C., Y. Zhang, J. F. Tobin, D. V. Erbe, S. Ikemizu, S. J. Davis, M. L. Stahl, J. Seehra, W. S. Somers, and L. Mosyak. 2001. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature 410: 608-611.
24. Schwartz, J. C., X. Zhang, A. A. Fedorov, S. G. Nathenson, and S. C. Almo. 2001. Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature 410: 604-608.
25. Riley, J. L., M. Mao, S. Kobayashi, M. Biery, J. Burchard, G. Cavet, B. P. Gregson, C. H. June, and P. S. Linsley. 2002. Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. Proc. Natl. Acad. Sci. USA 99: 11790-11795.
26. McHugh, R. S., W. D. Ratnoff, R. Gilmartin, K. W. Sell, and P. Selvaraj. 1998. Detection of a soluble form of B7-1 (CD80) in synovial fluid from patients with arthritis using monoclonal antibodies against distinct epitopes of human B7-1. Clin. Immunol. Immunopathol. 87: 50-59.
27. Jeannin, P., G. Magistrelli, J. P. Aubry, G. Caron, J. F. Gauchat, T. Renno, N. Herbault, L. Goetsch, A. Blaecke, P. Y. Dietrich, et al. 2000. Soluble CD86 is a costimulatory molecule for human T lymphocytes. Immunity 13: 303-312.
28. Ip, W. K., C. K. Wong, T. F. Leung, and C. W. Lam. 2005. Elevation of plasma soluble T cell costimulatory molecules CTLA-4, CD28 and CD80 in children with allergic asthma. Int. Arch. Allergy Immunol. 137: 45-52.
29. Wong, C. K., L. C. Lit, L. S. Tam, E. K. Li, and C. W. Lam. 2005. Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology 44: 989-994.
30. Hock, B. D., J. L. O'Donnell, K. Taylor, A. Steinkasserer, J. L. McKenzie, A. G. Rothwell, and K. L. Summers. 2006. Levels of the soluble forms of CD80, CD86, and CD83 are elevated in the synovial fluid of rheumatoid arthritis patients. Tissue Antigens 67: 57-60.
31. Dennehy, K. M., F. Elias, G. Zeder-Lutz, X. Ding, D. Altschuh, F. Luhder, and T. Hunig. 2006. Cutting edge: monovalency of CD28 maintains the antigen dependence of T cell costimulatory responses. J. Immunol. 176: 5725-5729.
32. Evans, E. J., R. M. Esnouf, R. Manso-Sancho, R. J. Gilbert, J. R. James, C. Yu, J. A. Fennelly, C. Vowles, T. Hanke, B. Walse, et al. 2005. Crystal structure of a soluble CD28-Fab complex. Nat. Immunol. 6: 271-279.
33. Hunig, T., and K. Dennehy. 2005. CD28 superagonists: mode of action and therapeutic potential. Immunol. Lett. 100: 21-28.
34. Harper, K., C. Balzano, E. Rouvier, M. G. Mattei, M. F. Luciani, and P. Golstein. 1991. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J. Immunol. 147: 1037-1044.
35. Lafage-Pochitaloff, M., R. Costello, D. Couez, J. Simonetti, P. Mannoni, C. Mawas, and D. Olive. 1990. Human CD28 and CTLA-4 Ig superfamily genes are located on chromosome 2 at bands q33-q34. Immunogenetics 31: 198-201.
36. Howard, T. A., J. M. Rochelle, and M. F. Seldin. 1991. Cd28 and Ctla-4, two related members of the Ig supergene family, are tightly linked on proximal mouse chromosome 1. Immunogenetics 33: 74-76.
37. Fallarino, F., P. E. Fields, and T. F. Gajewski. 1998. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J. Exp. Med. 188: 205-210.
38. Lin, H., J. C. Rathmell, G. S. Gray, C. B. Thompson, J. M. Leiden, and M. L. Alegre. 1998. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28. J. Exp. Med. 188: 199-204.
39. Engelhardt, J. J., T. J. Sullivan, and J. P. Allison. 2006. CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism. J. Immunol. 177: 1052-1061.